To have a lenz covid vaccine compound could be huge, since it would be variant agnostic. We would be able to not only treat covid, but to prevent it, also, whether the virus mutates, or not.
I haven't heard management address this opportunity except perhaps in terms of a partnership and in large scale testing.
Does it really matter? It was filed prior to EUA rejection and the company is not going to do anything with it anyways. You see any partners or buyers stepping up in the past 4 months?
News 
Market Data 
Discover 
AI
